TY - JOUR
T1 - Variation in the Association between Antineoplastic Therapies and Venous Thromboembolism in Patients with Active Cancer
AU - Giustozzi, Michela
AU - Curcio, Antonio
AU - Weijs, Bob
AU - Field, Thalia S.
AU - Sudikas, Saulius
AU - Katholing, Anja
AU - Wallenhorst, Christopher
AU - Weitz, Jeffrey I.
AU - Martinez, Carlos
AU - Cohen, Alexander T.
N1 - Funding Information:
The initial work on this study was supported in part by Bayer Pharma AG, Germany. The financial sponsor did not contribute to the conception of the study and had no role in the design, execution, analysis, interpretation of data, or writing of the manuscript. This study was supported by Bayer Thrombosis Academy for Learning Education and Networking Training Program (unrestricted educational grant).
Publisher Copyright:
© 2020 Georg Thieme Verlag KG Stuttgart • New York.
PY - 2020/5
Y1 - 2020/5
N2 - Background Venous thromboembolism (VTE) is a major cause of death in cancer patients. Although patients with cancer have numerous risk factors for VTE, the relative contribution of cancer treatments is unclear.Objective The objective of this study is to evaluate the association between cancer therapies and the risk of VTE.Methods From UK Clinical Practice Research Datalink, data on patients with first cancer diagnosis between 2008 and 2016 were extracted along with information on hospitalization, treatments, and cause of death. Primary outcome was active cancer-associated VTE. To establish the independent effects of risk factors, adjusted subhazard ratios (adj-SHR) were calculated using Fine and Gray regression analysis accounting for death as competing risk.Results Among 67,801 patients with a first cancer diagnosis, active cancer-associated VTE occurred in 1,473 (2.2%). During a median observation time of 1.2 years, chemotherapy, surgery, hormonal therapy, radiation therapy, and immunotherapy were given to 71.1, 37.2, 17.2, 17.5, and 1.4% of patients with VTE, respectively. The active cancers associated with the highest risk of VTE-as assessed by incidence rates-included pancreatic cancer, brain cancer, and metastatic cancer. Chemotherapy was associated with an increased risk of VTE (adj-SHR: 3.17, 95% confidence interval [CI]: 2.76-3.65) while immunotherapy with a not significant reduced risk (adj-SHR: 0.67, 95% CI: 0.30-1.52). There was no association between VTE and radiation therapy (adj-SHR: 0.91, 95% CI: 0.65-1.27) and hormonal therapies.Conclusion VTE risk varies with cancer type. Chemotherapy was associated with an increased VTE risk, whereas with radiation and immunotherapy therapy, an association was not confirmed.
AB - Background Venous thromboembolism (VTE) is a major cause of death in cancer patients. Although patients with cancer have numerous risk factors for VTE, the relative contribution of cancer treatments is unclear.Objective The objective of this study is to evaluate the association between cancer therapies and the risk of VTE.Methods From UK Clinical Practice Research Datalink, data on patients with first cancer diagnosis between 2008 and 2016 were extracted along with information on hospitalization, treatments, and cause of death. Primary outcome was active cancer-associated VTE. To establish the independent effects of risk factors, adjusted subhazard ratios (adj-SHR) were calculated using Fine and Gray regression analysis accounting for death as competing risk.Results Among 67,801 patients with a first cancer diagnosis, active cancer-associated VTE occurred in 1,473 (2.2%). During a median observation time of 1.2 years, chemotherapy, surgery, hormonal therapy, radiation therapy, and immunotherapy were given to 71.1, 37.2, 17.2, 17.5, and 1.4% of patients with VTE, respectively. The active cancers associated with the highest risk of VTE-as assessed by incidence rates-included pancreatic cancer, brain cancer, and metastatic cancer. Chemotherapy was associated with an increased risk of VTE (adj-SHR: 3.17, 95% confidence interval [CI]: 2.76-3.65) while immunotherapy with a not significant reduced risk (adj-SHR: 0.67, 95% CI: 0.30-1.52). There was no association between VTE and radiation therapy (adj-SHR: 0.91, 95% CI: 0.65-1.27) and hormonal therapies.Conclusion VTE risk varies with cancer type. Chemotherapy was associated with an increased VTE risk, whereas with radiation and immunotherapy therapy, an association was not confirmed.
KW - antineoplastic agents
KW - chemotherapy
KW - immunotherapy
KW - radiotherapy
KW - venous thromboembolism
KW - RISK-FACTORS
KW - DISEASE
KW - COHORT
KW - COMPLICATIONS
KW - THROMBOSIS
KW - BURDEN
U2 - 10.1055/s-0040-1709527
DO - 10.1055/s-0040-1709527
M3 - Article
C2 - 32369855
SN - 0340-6245
VL - 120
SP - 847
EP - 856
JO - Thrombosis and Haemostasis
JF - Thrombosis and Haemostasis
IS - 5
ER -